|
Clinical Trials Headlines
Early Cancer Detection Via New Blood Test: Research In The Early Stages Of Clinical Trials
A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer. Prof. Kapelushnik of BGU's Faculty of Health Sciences and his team developed a device that illuminates cancer cells with less than a teaspoon of blood...
Wed, 22 Feb 2012 00:00:00 PST - Source:MedNewsToday
Drug Combo Kills Pancreatic Cancer Cells
Combining gemcitabine with MRK003, an experimental drug, triggers a chain of events leading to pancreatic cancer cell death, researchers from Cambridge reported in the Journal of Experimental Medicine. The researchers explained that when the two drugs are combined, the effect of each one is multiplied, thus intensifying the destruction of pancreatic cancer cells...
Tue, 21 Feb 2012 09:00:00 PST - Source:MedNewsToday
Implantable Microchip Delivers Medicine To Women With Osteoporosis
Osteoporosis patients could soon ditch daily injection pens for an implantable microchip that releases medication at the push of a remote-controlled button, reports a new study appearing in the journal Science Translational Medicine...
Sat, 18 Feb 2012 00:00:00 PST - Source:MedNewsToday
Preventing 'Absence Seizures' In Children: New Drugs Show Promise
A team led by a University of British Columbia professor has developed a new class of drugs that completely suppress absence seizures - a brief, sudden loss of consciousness - in rats, and which are now being tested in humans. Absence seizures, also known as "petit mal seizures," are a symptom of epilepsy, most commonly experienced by children...
Fri, 17 Feb 2012 01:00:00 PST - Source:MedNewsToday
Helping Patients Tackle Geographic Challenges To Access Clinical Trials
As oncologists already know and newly diagnosed lung cancer patients learn, the kind of treatment given to patients is increasingly becoming dependent on the specific gene mutation present in the cancer...
Fri, 17 Feb 2012 01:00:00 PST - Source:MedNewsToday
Bureaucracy May Be Putting Lives At Risk, Europe
A European Parliament event to discuss how EU legislation has negatively affected the treatment received by children and adolescents has marked International Childhood Cancer Day - 15th February...
Wed, 15 Feb 2012 04:00:00 PST - Source:MedNewsToday
Medical Researchers Discover 'Very Promising' Treatment For Huntington Disease
Medical researchers at the University of Alberta have discovered a promising new therapy for Huntington disease that restores lost motor skills and may delay or stop the progression of the disease based on lab model tests, says the lead researcher...
Wed, 15 Feb 2012 01:00:00 PST - Source:MedNewsToday
Brain MRIs May Provide An Early Diagnostic Marker For Dyslexia
Children at risk for dyslexia show differences in brain activity on MRI scans even before they begin learning to read, finds a study at Children's Hospital Boston. Since developmental dyslexia responds to early intervention, diagnosing children at risk before or during kindergarten could head off difficulties and frustration in school, the researchers say...
Tue, 24 Jan 2012 02:00:00 PST - Source:MedNewsToday
Human Hookworm Vaccine Trial
The Na-GST-1 antigen, a candidate for the first human hookworm vaccine developed by the Sabin Vaccine Institute (Sabin), has entered a Phase 1 human trial in Brazil, according to Sabin. For the vaccine product development partnership (PDP) headquartered at Sabin, the clinical trial is a considerable achievement. Worldwide, almost 600 million individuals are infected by human hookworm...
Fri, 20 Jan 2012 08:00:00 PST - Source:MedNewsToday
Impetigo - Ozenoxacin Phase lll Trial
The pharmaceutical company Ferrer has received approval to start phase III human trials of ozenoxacin, formulated as a topical treatment for infectious skin conditions. In February 2012, participants are expected to enter the multicenter, randomized, placebo controlled, parallel, double-blinded superiority clinical study, which is scheduled to complete in 2013...
Fri, 20 Jan 2012 08:00:00 PST - Source:MedNewsToday
New Drug For Advanced Colorectal Cancer Shows Promise In Trial
An experimental drug for advanced colorectal cancer that available treatments have failed to halt, has shown promise in a clinical trial, says Bayer HealthCare, the company that makes it. The results of the phase III trial show that compared to placebo, regorafenib slowed tumor growth and extended survival...
Wed, 18 Jan 2012 03:00:00 PST - Source:MedNewsToday
Medivation And Pfizer Axe their new Alzheimer's drug Dimebon
Pfizer Inc. and Medivation, Inc. announced results from their 'CONCERT' trial today. CONCERT is a Phase 3 trial that evaluated dimebon (latrepirdine), which is used to treat patients with mild-to-moderate Alzheimer's disease. Dimebon is added to ongoing treatment with donepezil HCL tablets...
Tue, 17 Jan 2012 12:00:00 PST - Source:MedNewsToday
Preoperative Breast Cancer Treatment May Be Improved By Combining 2 Anti-HER2 Drugs
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent...
Tue, 17 Jan 2012 02:00:00 PST - Source:MedNewsToday
Research Misconduct Revealed in UK
A BMJ survey revealed that over one in ten (13%) UK based scientists or doctors have witnessed that colleagues intentionally changed or fabricated data during their research in order to get published, whilst 6% of respondents reported they are aware of possible research misconduct at their institution, that has not been accurately investigated...
Mon, 16 Jan 2012 10:00:00 PST - Source:MedNewsToday
In Ovarian Cancer, Faulty Proteins May Prove Significant In Identifying New Treatments
OHSU Knight Cancer Institute study results suggest that more patients than initially thought could potentially be treated with a new class of drugs, PARP inhibitors A constellation of defective proteins suspected in causing a malfunction in the body's ability to repair its own DNA could be the link scientists need to prove a new class of drugs will be effective in treating a...
Mon, 16 Jan 2012 00:00:00 PST - Source:MedNewsToday
Missing Data - A Serious Problem In Clinical Research
Missing data is a serious problem in clinical research given that it distorts the scientific record and prevents clinical decisions from being based on the best evidence available. As part of an in-depth BMJ review on the subject, experts on bmj.com warn that patients can be harmed through missing clinical trial data, leading to unnecessary costs to health systems...
Fri, 06 Jan 2012 10:00:00 PST - Source:MedNewsToday
Marinus Pharmaceuticals Experimental Epilepsy Treatment Shows Promise In Open-Label Extension Study
Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures (POS), reported positive data in the open-label extension follow up to the company's Phase 2 clinical trial. The data reflects the replication of the effects seen in the double-blind study...
Sun, 01 Jan 2012 01:00:00 PST - Source:MedNewsToday
Jennerex Announces First Patient Treated In Phase 2a Clinical Trial Of JX-594 As A Neoadjuvant Therapy In Colorectal Cancer
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver...
Sun, 01 Jan 2012 00:00:00 PST - Source:MedNewsToday
Human Trials Initiated For New HIV Vaccine
In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George's University London, Imperial College, Hull York Medical School (HYMS; University of York) and the Medical Research Council Clinical Trial Unit) and from the Infectious Dis...
Sun, 01 Jan 2012 00:00:00 PST - Source:MedNewsToday
"Science" Names HIV Prevention Trial As Breakthrough Of The Year
Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." FHI 360 congratulates our HPTN 052 collaborating partners on this important achievement. This is the second year in a row that Science selected a trial for which FHI 360 provided scientific leadership and operational support...
Sat, 31 Dec 2011 00:00:00 PST - Source:MedNewsToday
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease
Abbott (NYSE: ABT) announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit™ drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking)...
Sat, 31 Dec 2011 00:00:00 PST - Source:MedNewsToday
Denali Concrete Management Inc. Announces The Commencement Of Patient Enrollment For The Phase 3 Dry Eye Syndrome Study
Denali Concrete Management Inc. (OTCBB: DCMG) announced that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel...
Sat, 31 Dec 2011 00:00:00 PST - Source:MedNewsToday
Neuralstem's NSI-189 Trial In Major Depressive Disorder Receives FDA Approval To Advance To Phase Ib
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed patients...
Thu, 29 Dec 2011 01:00:00 PST - Source:MedNewsToday
Presentations Highlight Results Of Clinical Data For MLN8237 And VELCADE® In The Treatment Of Lymphoma
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) reported the presentation of results from a phase 2 trial evaluating MLN8237, an investigational inhibitor of Aurora A kinase, in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma (NHL)...
Fri, 23 Dec 2011 01:00:00 PST - Source:MedNewsToday
Novartis Announces Termination Of ALTITUDE Study With Rasilez®/ Tekturna® In High-Risk Patients With Diabetes And Renal Impairment
Novartis announced that following the seventh interim review of data from the ALTITUDE study with Rasilez®/Tekturna® (aliskiren), a decision to terminate the trial has been taken on the recommendation of the independent Data Monitoring Committee (DMC) overseeing the trial...
Thu, 22 Dec 2011 01:00:00 PST - Source:MedNewsToday
|
|
|
